Literature DB >> 18333494

Infectious diseases investment decision evaluation algorithm: a quantitative algorithm for prioritization of naturally occurring infectious disease threats to the U.S. military.

W Neal Burnette1, Charles H Hoke, John Scovill, Kathryn Clark, Jerry Abrams, Lynn W Kitchen, Kevin Hanson, Thomas J Palys, David W Vaughn.   

Abstract

Identification of the most significant infectious disease threats to deployed U.S. military forces is important for developing and maintaining an appropriate countermeasure research and development portfolio. We describe a quantitative algorithmic method (the Infectious Diseases Investment Decision Evaluation Algorithm) that uses Armed Forces Medical Intelligence Center information to determine which naturally occurring pathogens pose the most substantial threat to U.S. deployed forces in the absence of specific mitigating countermeasures. The Infectious Diseases Investment Decision Evaluation Algorithm scores the relative importance of various diseases by taking into account both their severity and the likelihood of infection on a country-by-country basis. In such an analysis, the top three endemic disease threats to U.S. deployed forces are malaria, bacteria-caused diarrhea, and dengue fever.

Entities:  

Mesh:

Year:  2008        PMID: 18333494     DOI: 10.7205/milmed.173.2.174

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  5 in total

1.  Forecasting dengue vaccine demand in disease endemic and non-endemic countries.

Authors:  Ananda Amarasinghe; Ole Wichmann; Harold S Margolis; Richard T Mahoney
Journal:  Hum Vaccin       Date:  2010-09-01

Review 2.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

3.  Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.

Authors:  Shuenn-Jue Wu; Dan Ewing; Appavu K Sundaram; Hua-Wei Chen; Zhaodong Liang; Ying Cheng; Vihasi Jani; Peifang Sun; Gregory D Gromowski; Rafael A De La Barrera; Megan A Schilling; Nikolai Petrovsky; Kevin R Porter; Maya Williams
Journal:  Microorganisms       Date:  2022-05-16

4.  Development of an internally controlled real-time reverse transcriptase PCR assay for pan-dengue virus detection and comparison of four molecular dengue virus detection assays.

Authors:  Jesse J Waggoner; Janaki Abeynayake; Malaya K Sahoo; Lionel Gresh; Yolanda Tellez; Karla Gonzalez; Gabriela Ballesteros; Angel Balmaseda; Kumudu Karunaratne; Eva Harris; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

Review 5.  Malaria and other vector-borne infection surveillance in the U.S. Department of Defense Armed Forces Health Surveillance Center-Global Emerging Infections Surveillance program: review of 2009 accomplishments.

Authors:  Mark M Fukuda; Terry A Klein; Tadeusz Kochel; Talia M Quandelacy; Bryan L Smith; Jeff Villinski; Delia Bethell; Stuart Tyner; Youry Se; Chanthap Lon; David Saunders; Jacob Johnson; Eric Wagar; Douglas Walsh; Matthew Kasper; Jose L Sanchez; Clara J Witt; Qin Cheng; Norman Waters; Sanjaya K Shrestha; Julie A Pavlin; Andres G Lescano; Paul C F Graf; Jason H Richardson; Salomon Durand; William O Rogers; David L Blazes; Kevin L Russell; Hoseah Akala; Joel C Gaydos; Robert F DeFraites; Panita Gosi; Ans Timmermans; Chad Yasuda; Gary Brice; Fred Eyase; Karl Kronmann; Peter Sebeny; Robert Gibbons; Richard Jarman; John Waitumbi; David Schnabel; Allen Richards; Dennis Shanks
Journal:  BMC Public Health       Date:  2011-03-04       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.